Pravastatin Reverses Established Radiation-Induced Cutaneous and Subcutaneous Fibrosis in Patients with Head and Neck Cancer: Results of the Biology-Driven Phase Ii Clinical Trial Pravacur

Previous preclinical investigations based on the inhibition of the Rho/ROCK/CTGF pathway brought the biological rationale for this bicentric phase II clinical trial on the use of statins for the treatment of established radio-induced fibrosis. This trial showed that pravastatin (40mg/day for 12 months) is a safe and efficient anti-fibrotic agent in patients with established grade ≥2 cutaneous and subcutaneous fibrosis after head and neck cancer radiotherapy. These results support the concept of fibrosis reversibility.

http://bit.ly/2GNaqjp